儿童肺动脉高压早期积极治疗改善预后
TOPP-2注册研究纳入445例新诊断、经导管确诊的WSPH第1组儿童肺动脉高压患者,评估真实世界初始治疗策略与结局的关系。结果显示,基线即用双联治疗的患者死亡/移植风险低于1年内才升级至双联的单药患者(HR=0.30),基线即用含肠外前列环素三联治疗的患者风险低于1年内才升级至肠外治疗者(HR=0.28),支持 upfront 联合优于序贯联合。
要点
- 双联治疗为最常见基线方案(40.2%),其次为单药(29.0%)。
- 基线双联较1年内升级至双联者死亡/移植风险更低(HR=0.30)。
- 基线含肠外前列环素三联较1年内升级至肠外者风险更低(HR=0.28)。
核心结论
- 儿童肺动脉高压早期积极联合治疗与更好的无移植生存相关,支持初始即联合而非序贯升级。
研究设计与样本
- TOPP-2全球注册研究(NCT02610660)纳入445例新诊断、经导管确诊的WSPH第1组儿童肺动脉高压患者。
- 基线治疗策略定义为诊断后3个月内所接受的药物,主要终点为死亡或肺移植。
主要发现
- 基线双联治疗最常见(40.2%),其次为单药(29.0%)。
- PAH靶向治疗中磷酸二酯酶5抑制剂最常见(72.4%),内皮素受体拮抗剂次之(59.3%)。
- 校正诊断时疾病严重度后,基线双联患者死亡/移植风险低于1年内由单药升级至双联者(HR=0.30,95%CI=0.16-0.56,p<0.001)。
- 基线含肠外前列环素三联患者死亡/移植风险低于1年内由肠内/吸入治疗升级至肠外者(HR=0.28,95%CI=0.15-0.50,p<0.001)。
临床怎么用
- 对低风险儿童PAH患者可考虑初始双联治疗,对高风险患者可考虑初始含肠外前列环素的三联治疗。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric pulmonary arterial hypertension (PAH) carries high mortality with 81% 5-year transplant-free survival. The global Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension-2 (TOPP-2; NCT02610660) registry was created to assess the treatments and outcomes of newly diagnosed pediatric PAH patients. This study evaluates real-world treatment strategies and their relationship with outcomes. METHODS: Within TOPP-2, 445 subjects with newly diagnosed, catheterization-confirmed WSPH Group 1 pediatric PAH were enrolled. Treatment regimens were classified as none, calcium channel blocker monotherapy, PAH-targeted Monotherapy (Mono), Dual, Triple (enteral/inhaled only), or triple including parenteral prostanoid (TripleX). Baseline treatment strategy was defined as medications received three months following diagnosis. Primary clinical endpoint was death or lung transplantation. RESULTS: Dual therapy was the most common baseline treatment regimen (40.2%), followed by Monotherapy (29.0%). Phosphodiesterase type 5 inhibitors were the most common class of PAH-targeted therapy (72.4%) followed by endothelin receptor antagonists (59.3%). Adjusting for disease severity at diagnosis, baseline Dual patients had lesser hazard of death/transplant than Mono patients escalating to Dual by year one (HR=0.30, 95% CI=0.16-0.56, p<0.001). Baseline TripleX patients had lesser hazard of death/transplant than those started on enteral/inhaled therapy only and escalated to parenteral by year one (HR=0.28, 95% CI=0.15-0.50, p<0.001). DISCUSSION: A wide range of pediatric PAH initial medication strategies were observed in the TOPP-2 registry. Therapy regimen escalation within the first year, to Dual for lower-risk patients or to TripleX for higher-risk patients, was associated with worse outcomes compared to those treated more aggressively upfront, supporting upfront over sequential combination therapies.
引用
- Frank BS, Beghetti M, Berger RMF, et al. Improved Outcomes with Early Aggressive Therapy in Pediatric Pulmonary Hypertension. Eur Respir J. 2026. PMID: 42562588. doi:10.1183/13993003.00327-2026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。